Epstein-Barr Virus (EBV)-Positive Diffuse Large B-cell Lymphoma Masquerading As Lupus Pneumonitis in a Young Woman With Systemic Lupus Erythematosus: A Diagnostic Odyssey. [PDF]
Anya OO, Mosallaei S, Wysham N.
europepmc +1 more source
When Small Cells Matter: Diagnosing Bladder Small Cell Carcinoma on Urine Cytology
Small cell carcinoma of the bladder is rare, aggressive and diagnostically challenging on urine cytology. We report a case detected in urine and confirmed by cell block immunohistochemistry, highlighting the importance of careful assessment and limitations of the Paris System.
Haley Corbin +3 more
wiley +1 more source
Zhang B, Xie Y, Shen M, et al. Multiplexed imaging mass cytometry elicits p-S6 as a therapeutic and prognostic factor in diffuse large B-cell lymphoma. Blood Adv. 2025;9(13):3249-3262. [PDF]
europepmc +1 more source
Predictive model for survival outcomes in rare primary glandular diffuse large B-cell lymphoma. [PDF]
Lu J, Liang C, Zhu X.
europepmc +1 more source
This meta‐analysis demonstrates high diagnostic accuracy of computer‐assisted methods in pancreatic EUS‐FNA cytology (AUC 0.92–0.96) and supports an integrated, cytopathologist‐led workflow in which artificial intelligence functions as an adjunct to diagnostic interpretation and on‐site evaluation (ROSE). Created in BioRender. Mohamed Mirzan, A. (2026)
Al‐Amaan Mohamed Mirzan, Roberto Dina
wiley +1 more source
Retinal vasculitis as a presenting sign of Epstein-Barr virus positive diffuse large B-cell lymphoma: a case report. [PDF]
Yavari N +11 more
europepmc +1 more source
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi +13 more
wiley +1 more source
Atypical Ulcerated Cutaneous Presentation of Diffuse Large B-Cell Lymphoma: A Case Report. [PDF]
Nogueira P +4 more
europepmc +1 more source
The different face of skin‐rash induced by brentuximab vedotin
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri +11 more
wiley +1 more source

